3 Stocks Raising The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 122 points (-0.7%) at 17,326 as of Friday, Nov. 13, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,130 issues advancing vs. 1,809 declining with 163 unchanged.

The Drugs industry currently sits up 1.6% versus the S&P 500, which is down 0.8%. Top gainers within the industry include

Mylan

(

MYL

), up 13.1%,

Mallinckrodt

(

MNK

), up 7.0%,

Illumina

(

ILMN

), up 6.9%,

Endo International

(

ENDP

), up 4.7% and

Dr Reddy Laboratories

(

RDY

), up 3.9%. On the negative front, top decliners within the industry include

Perrigo

(

PRGO

), down 6.6%, and

Novartis

(

NVS

), down 0.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Vertex Pharmaceuticals

(

VRTX

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $4.92 (4.2%) to $122.22 on light volume. Thus far, 649,362 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $116.78-$122.52 after having opened the day at $117.13 as compared to the previous trading day's close of $117.30.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $29.0 billion and is part of the health care sector. Shares are down 1.3% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Vertex Pharmaceuticals

as a

sell

. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity. Get the full

Vertex Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Amgen

(

AMGN

) is up $1.79 (1.2%) to $152.77 on average volume. Thus far, 1.6 million shares of Amgen exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $148.00-$153.52 after having opened the day at $150.68 as compared to the previous trading day's close of $150.98.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $118.3 billion and is part of the health care sector. Shares are down 5.2% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

AbbVie

(

ABBV

) is up $0.34 (0.6%) to $60.58 on light volume. Thus far, 2.7 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.8 million shares. The stock has ranged in price between $58.89-$60.97 after having opened the day at $60.01 as compared to the previous trading day's close of $60.23.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $99.5 billion and is part of the health care sector. Shares are down 8.0% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts who rate AbbVie a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...